$NVO and $DNA partnership #NovoNordisk and #Ginkgo have created a flexible and scalable new model for their R&D partnership. Together, the partners aim to improve the manufacturing of Novo Nordisk's #medicines for serious #ChronicDiseases, including #diabetes and #obesity #medications. The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio. Marcus Schindler, Novo Nordisk EVP and CSO: "We have been very pleased with the progress made in our initial work with Ginkgo focused on exploring strategies for a more effective future production process. We look forward to leveraging Ginkgo's synthetic biology platform across our R&D pipeline, from discovery through new ways of manufacturing, in this broader strategic partnership. Moreover, we are eager to explore more flexible models for external partnerships and this agreement allows Novo Nordisk to start more projects with Ginkgo in a faster and more agile manner." Jason Kelly, CEO and co-founder at Ginkgo Bioworks: "Novo Nordisk has played an important role in shaping the landscape for pharmaceutical products in the 21st century. We're so excited to expand our partnership to help them achieve their ambitious and global goals. With this deal structure, Novo Nordisk can easily access the entire expanse of Ginkgo's pharma services from discovery through manufacturing. Our teams share a deep passion for discovering, developing, and manufacturing innovative therapeutics for serious chronic diseases that affect billions of people around the world. We are honored to work shoulder-to-shoulder with the brilliant scientists, engineers, and developers at Novo Nordisk to help change disease outcomes for patients around the world." Discl: Long $DNA - #SynBio #StocksInFocus
$DNA cont'd Ginkgo Bioworks is a leading horizontal platform for cell programming that provides flexible, end-to-end services across diverse markets. Let me share some details about their platform: #Foundries: Ginkgo’s Bioworks Foundries are #BiologicalFactories where they automate and scale the process of #OrganismEngineering. These foundries allow engineers to prototype thousands of #BiologicalDesigns. They leverage state-of-the-art technology, including #DNAsynthesis, laboratory automation, and high-performance analytics. #Codebase: Ginkgo’s Codebase is their #BiologicalPortfolio. Just as software engineers draw on existing libraries of code to write new programs, Ginkgo’s organism engineers start from their growing codebase of cells, enzymes, and #GeneticPrograms. This allows them to jumpstart new projects and drive discoveries across different industries. Embracing #Biodiversity: Ginkgo explores and expands the metabolic map by learning from biodiversity. The #NaturalWorld has been evolving new #Chemistries for over four billion years, and Ginkgo taps into this diversity to find new pathways for sustainable #BioProducts. Learning From #Data: Ginkgo’s foundry-codebase feedback loop combines machine learning with meaningful biological insights. They constantly test and redesign enzymes, uncovering solutions that may not be found in textbooks. In summary, Ginkgo Bioworks is at the forefront of #CellProgramming, enabling #Biotechnology advancements across various fields, from food to fragrance to pharmaceuticals. While it’s challenging to definitively say if they have the “most advanced” platform, they are certainly a major player in the field. Keep in mind that the landscape is dynamic, and other companies and research institutions also contribute to advancing cell programming technology. Discl: Long $DNA stock